ACTIVE SPECIFIC IMMUNOTHERAPY IN THE MANAGEMENT OF ADENOCARCINOMA OF THE PANCREAS

Active specific immunotherapy for pancreatic adenocarcinoma and subseq uent immunohistochemical analysis of tumour tissue have not been previ ously reported. To date, the therapy of pancreatic adenocarcinoma has been largely unsuccessful. A patient treated with a therapeutic 'cance r vaccine' and the immunological impact on the primary tumour of this potential new therapy are described. To the authors' knowledge, this i s both the first patient to be treated with active specific immunother apy for pancreatic adenocarcinoma and the first to be studied immunolo gically by flow cytometry and immunohistochemistry with an apparent po sitive clinical impact.